194 related articles for article (PubMed ID: 28416959)
1. Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Kwon BS; Park JH; Kim WS; Song JS; Choi CM; Rho JK; Lee JC
Tuberc Respir Dis (Seoul); 2017 Apr; 80(2):187-193. PubMed ID: 28416959
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
[TBL] [Abstract][Full Text] [Related]
3. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.
Becker A; Crombag L; Heideman DA; Thunnissen FB; van Wijk AW; Postmus PE; Smit EF
Eur J Cancer; 2011 Nov; 47(17):2603-6. PubMed ID: 21784628
[TBL] [Abstract][Full Text] [Related]
4. Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI.
Xia GH; Zeng Y; Fang Y; Yu SR; Wang L; Shi MQ; Sun WL; Huang XE; Chen J; Feng JF
Cancer Biol Med; 2014 Dec; 11(4):270-6. PubMed ID: 25610713
[TBL] [Abstract][Full Text] [Related]
5. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
Zhang Q; Ke E; Niu F; Deng W; Chen Z; Xu C; Zhang X; Zhao N; Su J; Yang J; Yan H; Wu Y; Zhou Q
Oncotarget; 2017 Jan; 8(3):4994-5002. PubMed ID: 27999211
[TBL] [Abstract][Full Text] [Related]
6. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
[TBL] [Abstract][Full Text] [Related]
7. Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Hida T; Yatabe Y
Clin Lung Cancer; 2017 Nov; 18(6):698-705.e2. PubMed ID: 28596108
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
Yoshida T; Kuroda H; Oya Y; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
Lung Cancer; 2017 Jul; 109():89-91. PubMed ID: 28577956
[TBL] [Abstract][Full Text] [Related]
10. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
Lee CK; Davies L; Wu YL; Mitsudomi T; Inoue A; Rosell R; Zhou C; Nakagawa K; Thongprasert S; Fukuoka M; Lord S; Marschner I; Tu YK; Gralla RJ; Gebski V; Mok T; Yang JC
J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28376144
[TBL] [Abstract][Full Text] [Related]
14. Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Gao W; He J; Jin SD; Xu J; Yu TF; Wang W; Zhu Q; Dai H; Wu H; Liu YQ; Shu YQ; Guo RH
Onco Targets Ther; 2019; 12():9495-9504. PubMed ID: 31819477
[TBL] [Abstract][Full Text] [Related]
15. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
[TBL] [Abstract][Full Text] [Related]
16. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
[TBL] [Abstract][Full Text] [Related]
18. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
20. The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events.
Sakata Y; Kawamura K; Shingu N; Hiroshige S; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Nakano A; Ichikado K
Asia Pac J Clin Oncol; 2020 Apr; 16(2):e113-e117. PubMed ID: 30506897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
